Two major therapies, targeting cancer growth have been associated with hyperglycemia; mTOR inhibitors (Everolimus and Temsirolimus) and tyrosine kinase inhibitors (Nilotinib and Pazopanib) [17]. This evidence concerns the gene MTOR and Hyperglycemia.